Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial

Diabetes Technology and Therapeutics

Volumn 13, Issue 6, 2011, Pages 607-614

  Van Bon, Arianne C ^a   Bode, Bruce W ^b   Sert Langeron, Caroline ^c   DeVries, J Hans ^a   Charpentier, Guillaume ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

^d CENTRE HOSPITALIER SUD FRANCILIEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO;

ADULT; AGED; ARTICLE; CATHETER OCCLUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC KETOACIDOSIS; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; STATISTICS AS TOPIC; TIME FACTORS;

EID: 79957614885     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2010.0224     Document Type: Article

References (7)

1. Becker RH: Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 2007;9:109-121.
2. Hoogma RP, Schumicki D: Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006;38:429-433. (Pubitemid 44047966)
3. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2005;28(Suppl 1):S4-S36.
4. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP: Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol 2008;2:450-455.
5. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendeert R: Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005;37: 702-707. (Pubitemid 41810494)
6. Garg SK, Rosenstock J, Ways K: Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005;11:11-17. (Pubitemid 43073084)
7. Kawamori R, Kadowaki T, Ishii H, Iwasaki M, Iwamoto Y: Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus. Diabetes Obes Metab 2009;11: 891-899.